Title: | Efficacy and safety of the pregnancy-IVI, an intravenous insulin protocol for pregnancy, following antenatal betamethasone in type 1 and type 2 diabetes |
Contributor(s): | Rowe, Christopher W (author); Watkins, Brendan (author); Brown, Karina (author); Delbridge, Matthew (author); Addley, Jordan (author); Woods, Andrew (author); Wynne, Katie (author) |
Publication Date: | 2021 |
Early Online Version: | 2021 |
DOI: | 10.1111/dme.14489 |
Handle Link: | https://hdl.handle.net/1959.11/63632 |
Abstract: | | Aims: Hyperglycaemia following antenatal corticosteroids is common in womenwith diabetes in pregnancy, and validated algorithms to maintain pregnancy-specificglucose targets are lacking. The Pregnancy-IVI, an intravenous-insulin (IVI) algo-rithm, has been validated in gestational diabetes" however, its performance in pre-existing diabetes (Type 1 and Type 2 diabetes) is not known. We hypothesised that Pregnancy-IVI would be superior to a generic Adult-IVI protocol (prior standard of care) following betamethasone in women with pre-existing diabetes.
Methods: A retrospective cohort study enrolled all women with pre-existing diabetes at a tertiary centre receiving betamethasone and treated with IVI according to one of two protocols: Adult-IVI (n = 73, 2014–2017) or Pregnancy-IVI (n = 62,2017–2020). The primary outcome was on-IVI glycaemic time-in-range (capillary blood glucose (BGL) 3.8–7.0 mmol/L). Secondary outcomes included time with critical hyperglycaemia (BGL > 10 mmol/L)" occurrence of maternal hypoglycaemia (BGL < 3.8 mmol/l) and incidence of neonatal hypoglycaemia (BGL ≤ 2.5 mmol/L).Analysis was stratified by diabetes type.
Results: Overall, Pregnancy-IVI achieved a higher proportion of on-IVI time-in-range (70%, IQR 56–78%) compared to Adult-IVI (52%, IQR 41–69%, p < 0.0001).The duration of critical hyperglycaemia with Pregnancy-IVI was also reduced (2%[IQR 0–7] vs 8% [IQR 4–17], p < 0.0001), without an increase in hypoglycaemia. Glycaemic variability was significantly reduced with Pregnancy-IVI. No difference in the rate of neonatal hypoglycaemia was observed. The Pregnancy-IVI was most effective in women with Type 1 diabetes.
Conclusion: The Pregnancy-IVI algorithm is safe and effective when used following betamethasone in type 1 diabetes in pregnancy. Further study of women with type 2diabetes is required.
Publication Type: | Journal Article |
Source of Publication: | Diabetic Medicine, 38(4), p. 1-12 |
Publisher: | Wiley-Blackwell Publishing Ltd |
Place of Publication: | United Kingdom |
ISSN: | 1464-5491 0742-3071 |
Fields of Research (FoR) 2020: | 3202 Clinical sciences |
Socio-Economic Objective (SEO) 2020: | tbd |
Peer Reviewed: | Yes |
HERDC Category Description: | C1 Refereed Article in a Scholarly Journal |
Appears in Collections: | Journal Article School of Science and Technology
|